<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066427</url>
  </required_header>
  <id_info>
    <org_study_id>SOGUG-2016-A- IEC(REN)-10</org_study_id>
    <secondary_id>2016-004011-12</secondary_id>
    <nct_id>NCT03066427</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.</brief_title>
  <acronym>INMUNOSUN</acronym>
  <official_title>Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the&#xD;
      appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the&#xD;
      immunotherapy, in addition to the approval of new active drugs in the following lines of&#xD;
      treatment.&#xD;
&#xD;
      There are currently two phase III trials in the first line of treatment in metastatic renal&#xD;
      cancer that include different combinations of treatment based on immunotherapy. If results of&#xD;
      these studies were positive, the therapeutic algorithm would be modified so that the&#xD;
      remaining drugs would have to be repositioned within the therapeutic decision scheme.&#xD;
&#xD;
      Sunitinib has previously demonstrated its benefit in patients who had failed to prior&#xD;
      treatment with cytokines, so it is likely to continue to be effective in patients who have&#xD;
      become resistant to treatment with new drugs based on immune checkpoint blockade.&#xD;
&#xD;
      This phase II study is developed to evaluate the activity of sunitinib after treatment with&#xD;
      immunotherapy-based regimens that are currently being developed within phase III clinical&#xD;
      trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with documented response according RECIST 1.1 criteria (complete response + partial response)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Time from start of treatment to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>12 months</time_frame>
    <description>Time from start of treatment to disease progression or death due to the illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the response</measure>
    <time_frame>12 months</time_frame>
    <description>Time from first response to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
    <description>Time from start of treatment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with documented response or disease stabilization according RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of individual events (hematologic events and not hematologic events)</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with each of the adverse event per grade</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Clear Cell Renal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib 50 mg/day, 4 weeks on/2weeks off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib 50 mg/d</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Eighteen years or older on the day of consent&#xD;
&#xD;
          -  2. Documented histological or cytological diagnosis of renal cell cancer with a&#xD;
             clear-cell component.&#xD;
&#xD;
          -  3. Patient must have progressed to at least one immune check point inhibitor-based&#xD;
             therapy (antiPD1, anti-PDL1 o antiCTLA4) for the first line&#xD;
&#xD;
          -  4. Measurable disease per RECIST 1.1 as determined by the investigator&#xD;
&#xD;
          -  5. The subjects should not present disease that may be subsidiary of surgical&#xD;
             treatment, radiotherapy or combined treatment with curative intent.&#xD;
&#xD;
          -  6. Recovery of toxicities related to any prior treatments to ≤ Grade 1 CTCAE v.4.03,&#xD;
             unless adverse event(s) are clinically nonsignificant and/or stable on supportive&#xD;
             therapy.&#xD;
&#xD;
          -  7. Eastern Cooperative Oncology Group Performance Status (PS) 0-2&#xD;
&#xD;
          -  8. Adequately controlled blood pressure (BP) with or without antihypertensive&#xD;
             medication to maintain a BP &lt;150/90 mmHg before the start of study treatment.&#xD;
&#xD;
          -  9. Adequate marrow function&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/mm3 (≥ 1.5 GI/L).&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm3 (≥ 100 GI/L).&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (≥ 5,6 mmol/L).&#xD;
&#xD;
          -  10. Adequate liver function&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 × ULN.&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN).&#xD;
&#xD;
          -  11. Adequate kidney function: calculated creatinine clearance ≥ 30 mL/min (≥ 0.5&#xD;
             mL/sec) using the Cockroft-Gault equation&#xD;
&#xD;
          -  12. Proteinuria &lt;2+ on urine test strip&#xD;
&#xD;
          -  13. Prothrombin Time (PT) or International Standard Ratio (INR) ≤ 1.2 x ULN.&#xD;
&#xD;
          -  14. Life expectancy &gt;3 months.&#xD;
&#xD;
          -  15. Patient able to ingest study drug and meet study follow-up requirements.&#xD;
&#xD;
          -  16. Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception&#xD;
&#xD;
          -  17. Female subjects of childbearing potential must not be pregnant at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Previous treatments with sunitinib are not permitted for the advanced or localized&#xD;
             disease.&#xD;
&#xD;
          -  2. Major surgery within 3 weeks of patient inclusion&#xD;
&#xD;
          -  3. Radiation therapy or embolization within 2 weeks of first dose of sunitinib&#xD;
&#xD;
          -  4. Previous treatment with immunosuppressive drugs such as cyclosporine, tacrolimus,&#xD;
             azathioprine, or long-term oral glucocorticoids taken prior to (3 months) patient&#xD;
             inclusion&#xD;
&#xD;
          -  5. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.&#xD;
&#xD;
          -  6. Current treatment on another clinical trial.&#xD;
&#xD;
          -  7. Treatment with known potent CYP3A4 inhibitors or inducers or that prolong the QT&#xD;
             interval, within 7 days prior to the inclusion.&#xD;
&#xD;
          -  8. Prior radiation therapy to &gt;25% of the bone marrow.&#xD;
&#xD;
          -  9. Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis,&#xD;
             or leptomeningeal disease.&#xD;
&#xD;
          -  10. Any gastrointestinal malabsorption disorder or any other condition that, in the&#xD;
             opinion of the investigator, may affect the absorption of sunitinib or increase the&#xD;
             risk of bleeding or perforation.&#xD;
&#xD;
          -  11. Presence of an unhealed wound or active ulcer.&#xD;
&#xD;
          -  12. Diarrhea grade III/IV in the screening period.&#xD;
&#xD;
          -  13. Diagnosis of any second malignancy within the last 3 years, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  14. Clinically significant cardio-cerebrovascular disease within 6 months prior to&#xD;
             initiation of treatment.&#xD;
&#xD;
          -  15. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any&#xD;
             grade that require treatment.&#xD;
&#xD;
          -  16. Corrected QT interval (QTc) interval &gt;500 msec.&#xD;
&#xD;
          -  17. Active hemoptysis within 6 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  18. Evidence of active bleeding or hemorrhagic diathesis.&#xD;
&#xD;
          -  19. Presence of endobronchial lesions and / or lesions that infiltrate large vessels.&#xD;
&#xD;
          -  20. Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg&#xD;
             PO daily for deep vein thrombosis prophylaxis is allowed).&#xD;
&#xD;
          -  21. Other clinically significant alterations:&#xD;
&#xD;
               -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
               -  Presence of an uncontrolled active infection.&#xD;
&#xD;
               -  Presence of uncontrolled or symptomatic hypothyroidism.&#xD;
&#xD;
               -  Moderate-severe liver disease (Child Pugh B-C).&#xD;
&#xD;
               -  Requirement for hemodialysis or peritoneal dialysis.&#xD;
&#xD;
               -  History of solid organ transplantation.&#xD;
&#xD;
          -  22. Pregnancy or breastfeeding.&#xD;
&#xD;
          -  23. Any disease that, in the opinion of the investigator, interferes with the&#xD;
             patient's ability to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Grande, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MD Anderson Cancer Center Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Suárez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier García del Muro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hestia Duran i Reynals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar Reig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María J Méndez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Regional Reina Sofia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Castellano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clear Cell Renal Carcinoma</keyword>
  <keyword>Sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

